Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?

Human nevi lack distinguishing senescence traits

(2016) Sieu Tran et al.   Aging-US

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

MITF Modulates Therapeutic Resistance through EGFR Signaling

(2015) Zhenyu Ji et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

(2015) William D. Tap et al.   NEOPLASIA

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

(2014) Amanda Lassen et al.   Molecular Cancer

Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression

(2014) Rickard Linnskog et al.   Molecular Oncology

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

(2014) Matteo S. Carlino et al.   Molecular Oncology

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells

(2014) Marie R. Webster et al.   Pigment Cell & Melanoma Research

Towards a Unified Model of RAF Inhibitor Resistance

(2014) D. B. Solit et al.   Cancer Discovery

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma

(2014) Marian M. Deuker et al.   Cancer Discovery

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors

(2014) Martin L. Sos et al.   Cell Reports

WNT5A-mediated  -catenin-independent signalling is a novel regulator of cancer cell metabolism

(2013) V. Sherwood et al.   CARCINOGENESIS

Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma

(2013) H. K. Bid et al.   CLINICAL CANCER RESEARCH

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma

(2013) Victoria Marsh Durban et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

A Wnt-er Migration: The Confusing Role of  -Catenin in Melanoma Metastasis

(2013) M. R. Webster et al.   Science Signaling

The Small GTPase ARF6 Stimulates  -Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis

(2013) A. H. Grossmann et al.   Science Signaling

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

The Role of the PI3K-AKT Pathway in Melanoma

(2012) Michael A. Davies   CANCER JOURNAL

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

(2012) Harkanwal Halait et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

(2012) Lise Hoejberg et al.   MELANOMA RESEARCH

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging molecular targets in melanoma invasion and metastasis

(2012) Jose L. Orgaz et al.   Pigment Cell & Melanoma Research

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

(2012) A. Gurney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wnt/ -Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma

(2012) T. L. Biechele et al.   Science Signaling

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

(2012) Hubing Shi et al.   Cancer Discovery

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin

(2011) Wei Wei et al.   Molecular Cancer

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF

(2011) F Xing et al.   ONCOGENE

Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching

(2011) Ossia M. Eichhoff et al.   Pigment Cell & Melanoma Research

The three M’s: melanoma, microphthalmia-associated transcription factor and microRNA

(2011) Rachel E. Bell et al.   Pigment Cell & Melanoma Research

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma

(2010) Sarah Beseme Nambotin et al.   JOURNAL OF HEPATOLOGY

The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report

(2010) Ossia M. Eichhoff et al.   MELANOMA RESEARCH

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

(2009) M. A. Davies et al.   CLINICAL CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Functional RET G691S polymorphism in cutaneous malignant melanoma

(2009) N Narita et al.   ONCOGENE

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma

(2009) M P O’Connell et al.   ONCOGENE

Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt

(2009) Michael P. O’Connell et al.   Pigment Cell & Melanoma Research

A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion

(2009) V. Jenei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activated Wnt/ss-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model

(2009) A. J. Chien et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation

(2008) S. K. Dissanayake et al.   CANCER RESEARCH

WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome

(2008) P. D. Da Forno et al.   CLINICAL CANCER RESEARCH

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

(2008) X. Jiang et al.   CLINICAL CANCER RESEARCH

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF

(2008) Claudia Wellbrock et al.   PLoS One